JP Morgan Chase
DNA icon

JP Morgan Chase’s Ginkgo Bioworks DNA Stock Holding History

JP Morgan Chase’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-610
Closed -$76K – 6624
2022
Q3 		$76K Buy
+610
New +$72.7K ﹤0.01% 5406

Other funds holding DNA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

JP Morgan Chase's DNA Position: Q2 2026 in Review

JP Morgan Chase increased its Ginkgo Bioworks (DNA) stake by 605% in Q2 2026, buying an estimated $962K and bringing the position to 134,040 shares worth $1.37M. The position accounts for ﹤0.01% of the portfolio, ranked #4463.

JP Morgan Chase first reported a position in DNA in Q3 2021 and has held it in 20 quarters since. The position peaked at $10.9M in Q1 2022. 183 funds tracked by Wall St. Rank hold DNA as of Q2 2026.

  • JP Morgan Chase held 134,040 shares of Ginkgo Bioworks worth $1.37M as of Q2 2026.
  • JP Morgan Chase bought 115,014 Ginkgo Bioworks shares in Q2 2026, an estimated $962K.
  • Ginkgo Bioworks made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #4463 holding.
  • JP Morgan Chase first reported a position in Ginkgo Bioworks in Q3 2021 and has held it in 20 quarters since.
  • JP Morgan Chase's Ginkgo Bioworks position peaked at $10.9M in Q1 2022.
  • 183 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.